Evidence map›Paper›PMID 37274772›Full record

ArticlePathology oncology research : POR2023

PD-1 and PD-L1 expression in rare lung tumors.

Marton Gyulai, Zsolt Megyesfalvi, Lilla Reiniger, Tunde Harko, Bence Ferencz, Luca Karsko, Laszlo Agocs, Janos Fillinger, Balazs Dome, Zoltan Szallasi and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathology oncology research : POR, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Marton GyulaiCounty Institute of Pulmonology, Torokbalint, Hungary.
Zsolt MegyesfalviNational Koranyi Institute of Pulmonology, Budapest, Hungary.
Lilla ReinigerInstitute of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Tunde HarkoNational Koranyi Institute of Pulmonology, Budapest, Hungary.
Bence FerenczNational Koranyi Institute of Pulmonology, Budapest, Hungary.
Luca KarskoNational Koranyi Institute of Pulmonology, Budapest, Hungary.
Laszlo AgocsNational Koranyi Institute of Pulmonology, Budapest, Hungary.
Janos FillingerNational Koranyi Institute of Pulmonology, Budapest, Hungary.
Balazs DomeNational Koranyi Institute of Pulmonology, Budapest, Hungary.
Zoltan SzallasiNational Koranyi Institute of Pulmonology, Budapest, Hungary.
Judit MoldvayNational Koranyi Institute of Pulmonology, Budapest, Hungary.
Országos Korányi Tbc és Pulmonológiai Intézet · HUNational Institute of Oncology · HUSemmelweis University · HUHarvard University · USHUN-REN Institute of Experimental Medicine · HU

Funding

Austrian Science Fund FWF I 3977Austrian Science Fund FWF I 4677
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

B7-H1 AntigenLung NeoplasmsBiomarkers, TumorHumansLungProgrammed Cell Death 1 ReceptorRetrospective StudiesB7-H1 AntigenBiomarkers, TumorProgrammed Cell Death 1 Receptoradenoid cystic carcinomamucoepidermoid carcinomaprogrammed cell death-1 (PD-1)programmed cell death ligand-1 (PD-L1)rare lung tumors

Identifiers

PMID37274772
PMCPMC10232779
OpenAlexW4377107798

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.